Zhong Yang Technology Co., Ltd. (6668)
TWSE TWSE Primary Summary
Zhong Yang Technology Co., Ltd. (6668) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zhong Yang Technology Co., Ltd. ever had a stock split?
Zhong Yang Technology Co., Ltd. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Mr. Jung-Chou Lee CEO | TWSE Exchange | TW0006668007 ISIN |
| TW Country | - Employees | 29 Sep 2021 Last Dividend | 3 Aug 2021 Last Split | - IPO Date |
Overview
Dna Group (T.R.) Ltd, originally established as D.N.A Biomedical Solutions Ltd, is an innovative company based in Tel Aviv-Yafo, Israel, that specializes in the development, manufacturing, and international marketing of advanced patented ultrasound systems. Since its inception in 2004, the company has made significant strides in offering cutting-edge diagnostic solutions across Israel, North America, East Asia, and other global markets. Committed to enhancing patient care, Dna Group (T.R.) Ltd focuses on creating technologies that aid in the diagnosis of bone strength and density, as well as the monitoring of conditions like osteoporosis in both adults and children. The renaming to Dna Group (T.R.) Ltd in November 2022 marked a new chapter in the company's mission to broaden its impact in the healthcare and biotechnology sectors. In addition to its core offerings, the company is also actively engaged in the development of oral drugs, further diversifying its contributions to medical science and healthcare.
Products and Services
- Patented Ultrasound Systems for Bone Strength and Density Diagnosis:
- Osteoporosis Monitoring Systems:
- Pharmacy and Clinic Utilization:
- Development of Oral Drugs:
An innovative range of systems designed to precisely diagnose the strength and density of bones. These high-tech solutions cater to the medical needs by assisting in the early detection of potential bone-related disorders, thereby enabling timely intervention.
Dna Group offers advanced monitoring solutions to detect and keep track of calcium leakage, a crucial factor in managing osteoporosis in adults and children. The widespread application of these systems plays a vital role in preventive healthcare, minimizing the risk of fractures and bone damage associated with osteoporosis.
The company's products are not only confined to hospital settings but are also designed for use by skilled professionals including physicians, nurses, and operators in pharmacies, clinics, and other healthcare facilities. This versatility ensures broader accessibility and convenience in patient care.
Expanding its horizons beyond diagnostic equipment, Dna Group (T.R.) Ltd is actively involved in the research and development of oral drugs. This initiative signifies the company's commitment to contributing to the advancement of therapeutic solutions and pharmaceutical innovation.
